Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 90Prostatic Neoplasms 55Lymphoma 34Leukemia 32Carcinoma, Non-Small-Cell Lung 31Multiple Myeloma 30Head and Neck Neoplasms 30Colorectal Neoplasms 29Squamous Cell Carcinoma of Head and Neck 28Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Colonic Neoplasms 24Leukemia, Myeloid, Acute 22Rectal Neoplasms 21Neoplasm Metastasis 20Sarcoma 19Ovarian Neoplasms 19Central Nervous System Neoplasms 18Uterine Cervical Neoplasms 17Hodgkin Disease 17Burkitt Lymphoma 15Brain Neoplasms 15Carcinoma, Ovarian Epithelial 14Pain 12Lymphoma, Follicular 12Urinary Bladder Neoplasms 11Lymphoma, Large B-Cell, Diffuse 11Fallopian Tube Neoplasms 11Endometrial Neoplasms 11Astrocytoma 11

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × Smoldering Multiple Myeloma × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡